
    
      Pts meeting eligibility criteria will be registered, providing the availability of material
      for molecular analysis. Tumour specimens and blood sample will be collected to perform
      genomic, ICH and proteomic analyses in order to identify the molecular characteristics of
      tumour.

      After the availability of KRAS evaluation, only the data of KRAS wild-type pts will be
      collected.

      Access to registration system will be allowed via web.

      Patients,KRAS wild-type receive:

      - Cetuximab+FOLFIRI: cetuximab 500 mg/ m² starting dose, following everytwo- week doses of
      500 mg/ m², given d1, followed after 1 hour by FOLFIRI: irinotecan 180 mg/m2 on day 1 with LV
      100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an
      intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU
      bolus injection on days 1 and 2
    
  